Compared with general internal medicine, which depends on episodic demand like colds, diabetes medicine is less exposed to economic and seasonal swings and builds a stable patient base through continuing visits. But cost containment continues, and consulting firms consistently note that simply opening and waiting no longer sustains above-average income.
In 2026, two regulatory changes reshaped the environment.
1. Macro environment — two regulatory changes
The FY2026 revision steered management quality through the fee structure
The core of the revision was using the fee structure to steer the quality of outpatient management for lifestyle-disease patients.
| Item | Key change |
|---|---|
| Lifestyle disease management fee (I) | Base points held (610 dyslipidemia / 660 hypertension / 760 diabetes). Blood testing at least once every six months made an explicit requirement |
| Lifestyle disease management fee (II) (333 points) | Specific drug treatment management and tumor marker management fees removed from bundling, now separately billable fee-for-service |
| Ophthalmology / dental coordination add-on | Newly created for patients with diabetes as the principal condition (60 points each, once per patient per year) |
| Care plan documents | Patient signature no longer required |
Making coordination with other specialties — anticipating complications such as diabetic retinopathy and periodontal disease — a rewarded activity is significant here. Overall, the revision reads as an adjustment that makes it easier to convert diabetes medicine's inherent strength, continuous multidisciplinary care guidance, directly into revenue.
Clinic opening regulations effective April 2026
Under the new system, several secondary medical areas — including parts of Tokyo's 23 wards, Kyoto, Osaka, Kobe, and Fukuoka — became candidates for designation as areas with excess outpatient physicians. Opening an insured clinic in a designated area now generally requires advance notification to the prefecture at least six months before opening.
The notification must state intent to contribute to locally underserved functions such as night and holiday care, home medical care, and public health work, and the prefecture may "request" provision of those functions. The request is not a legal order, but non-compliance carries an explanation obligation and, ultimately, escalation to recommendations, public disclosure, and shortening of the insured institution designation period (from six years to three or two).
For urban openings, location freedom is more constrained, and how community contribution is written into the practice plan now affects both whether you can open and how quickly you earn local trust.
2. Characteristics of newly opened clinics
Diabetes clinics are designed around a chronic-disease rhythm: patient acquisition takes time, but once established the base rarely erodes.
A tenant opening (132 m² at ¥12,000/tsubo) is estimated at roughly ¥43.9 million total investment, though some physicians open with minimal blood and urine testing equipment — so initial investment swings widely depending on scope of practice.
The defining acquisition challenge is that diabetes produces few symptoms early, so patients rarely arrive having recognized they have it. Advertising-driven rapid acquisition therefore does not work well; the levers are hospital-clinic referral relationships, inflow from health checks (including specific health checkups), and relationships with partner pharmacies. Cases exist of clinics reaching break-even with almost no marketing spend, through location selection based on local needs assessment plus referral relationships.
On facilities, practical requirements include in-clinic toilets for frequent urine testing, handwashing in consultation rooms, and adequate procedure room space. Nurses and administrative staff are essential; adding a registered dietitian if nutrition guidance is to be a revenue pillar, and a Certified Diabetes Educator of Japan (CDEJ) to assure guidance quality.
3. Revenue areas specific to diabetes medicine
Revenue design depends less on physician consultation value than on accumulating guidance management fees across a multidisciplinary team including nurses and registered dietitians.
Multidisciplinary guidance management fees
The core item is the diabetes dialysis prevention guidance management fee. Forming a dialysis prevention care team of physician, nurse (or public health nurse), and registered dietitian, and providing lifestyle guidance to patients at dialysis risk, allows billing 350 points once monthly (clinics may bill when requirements are met).
Combining this with the outpatient nutrition guidance fee (dietitian-provided: 260 points first in-person session, 200 thereafter; online patterns at 235 and 180) can, per published analyses, fully cover the personnel cost of nurses and dietitians.
The diabetes complication management fee (foot care) is another billable area for specialized care of high-risk diabetic foot patients under dedicated physician and nurse staffing.
Supporting this multidisciplinary model on quality is the CDEJ credential. Nurses, dietitians, pharmacists, laboratory technicians, and physical therapists earn it through practical experience, coursework, and examination, delivering patient education across diet, exercise, medication, and self-management. CDEJ staffing indirectly supports stable billing and continued visits by standardizing guidance and improving adherence.
Expanded CGM coverage
The biggest recent development on devices is expanded CGM coverage (FreeStyle Libre and similar). Insurance coverage extended to all diabetic patients on insulin therapy in 2022, and from 2024 a framework was established allowing CGM use for non-insulin patients under the selective treatment (senteiryoyo) scheme.
This allows offering CGM across three tiers — insured, selective treatment, and self-pay — making it easy to build into outpatient menus as an early education and lifestyle visualization tool for type 2 diabetes.
On drugs, SGLT2 inhibitors and GLP-1 receptor agonists (plus oral semaglutide and the GIP/GLP-1 dual agonist tirzepatide) have established themselves as standard options in type 2 diabetes, with prescribing opportunities expanding on weight and cardiorenal protection grounds.
Inflow from health checkups
Bridging pre-diabetic patients flagged for high blood glucose or borderline results into specific health guidance and lifestyle disease management is the classic route for capturing asymptomatic patients early. Running checkups in-house, or partnering with local screening organizations and corporate health insurance societies, produces a stable supply of new patients.
4. Self-pay services — designing the boundary around GLP-1
Self-pay in diabetes medicine is expanding rapidly around medical weight loss using GLP-1 receptor agonists — and simultaneously demands the most careful regulatory understanding.
The essential point is distinguishing, in both internal operations and advertising, that insured obesity treatment, insured type 2 diabetes treatment, and self-pay weight loss are clearly different things even within the same drug class.
Requirements on the insured side
Insured prescription of the obesity drug Wegovy (semaglutide) carries strict requirements. Eligibility is BMI 27 or above with two or more obesity-related conditions such as hypertension, dyslipidemia, or type 2 diabetes, or BMI 35 or above — in either case predicated on inadequate response to at least six months of diet and exercise therapy. Patients under 20, those with type 1 diabetes, and those with specific histories (medullary thyroid carcinoma, MEN2) are excluded.
Facility standards are also demanding: physicians with five or more years treating hypertension, dyslipidemia, type 2 diabetes, and obesity; specialist credentials from relevant societies or educational certification; and a full-time registered dietitian providing nutrition guidance. Online-only models structurally struggle to meet these.
The reality on the self-pay side
Self-pay GLP-1 weight loss serves patients who do not meet those strict standards, or who seek aesthetic or weight management outcomes. One diabetes clinic publishes ¥3,000 first visit and ¥1,500 return visit plus drug pricing: Wegovy ¥16,000–60,000 per 4 weeks, Zepbound from ¥26,000, Mounjaro from ¥17,600, and oral Rybelsus ¥4,500–17,500.
Note that Mounjaro and Rybelsus can be prescribed under insurance for type 2 diabetes patients while being self-pay for weight loss purposes. The same drug splits between insured and self-pay depending on indication and patient eligibility.
Meeting medical advertising guidelines
Recommended practice includes citing clinical trial data such as the STEP and SURMOUNT trials as the evidence base, detailing side effects and contraindications (including prohibition during pregnancy and breastfeeding), clearly displaying the distinction between self-pay and insured care, and stating policy on continuing patients treated elsewhere. Testimonials, before-and-after images, guarantee-style claims, and unclear pricing carry high advertising risk. Demonstrating publicly that services are provided within a diabetes specialist's appropriate-use and safety management framework matters for both trust and risk management.
5. Management implications
Management in 2026 depends on running two axes — quality of multidisciplinary insured care guidance, and appropriate design of self-pay services — along a single spine of specialization.
On the insured side, mandatory blood testing under fee (I) and the new coordination add-on both point toward rewarding data-driven planned management and complication-aware cross-specialty coordination. Reliably billing the dialysis prevention guidance fee, outpatient nutrition guidance fee, and complication management fee through a multidisciplinary team anchored by CDEJs and dietitians, while using all three CGM tiers to deepen early care education, is the proven route to raising both unit price and continuation rates.
On the self-pay side, GLP-1 medical weight loss is a substantial opportunity — inseparable from the risk of blurring the boundary against insured obesity treatment and facility standards, and of advertising non-compliance. Not compromising the position that "a diabetes and obesity specialist provides this within an appropriate-use framework" is the key to differentiating from aesthetic and online-only competitors and maintaining trust.
Patient acquisition continues to reward careful design of the chronic-disease routes — health checkup inflow and referral relationships — and in urban areas, writing community contribution into plans under the 2026 opening regulations affects both approval and early local trust.
6. How an AI EMR addresses these problems — feature by feature
In diabetes medicine, continuous data accumulates over years — HbA1c, glucose, weight, blood pressure, CGM traces, medication, diet and exercise records. Whether you can put that accumulation to work in both care and billing is what separates practices. Here is how Pottech's AI Karte supports it, feature by feature.
Feature 1: Billing and claims — don't leave multidisciplinary guidance fees on the table
An automated calculation engine checks bundling conflicts, exclusions, and frequency limits, and determines add-on eligibility automatically.
Revenue here is determined by accumulated guidance management fees: dialysis prevention guidance (350 points monthly), outpatient nutrition guidance (260 first / 200 thereafter), complication management. Each has detailed billing and documentation requirements, with different patient eligibility criteria, delivering professions, and intervals. Managed by hand, omissions are structurally inevitable.
On top of that, lifestyle disease management fee (I) now requires blood testing at least every six months. Tracking last-draw dates across hundreds of patients manually is impractical, so whether overdue patients can be surfaced automatically determines whether the requirement holds.
Feature 2: AI assistant — summarize long time series
Summarizes lab value trends and personalizes patient-facing explanations.
Diabetes care follows multiple indicators — HbA1c, weight, blood pressure, lipids — over years. Summarizing "what improved and what worsened over these six months," rather than reading a list of numbers, raises the quality of guidance within limited consultation time, and feeds directly into care plan documents. Generated patient explanations support the persuasion process in a treatment that depends on the patient's own behavior change.
Feature 3: Integrations and APIs — bring in CGM and patient app data
An OAuth2 gateway, MCP server, and HAPI FHIR enable integration with external systems and devices.
CGM can be offered across insured, selective treatment, and self-pay tiers, and is increasingly positioned as an early education tool in type 2 diabetes. But CGM's value only materializes when the trace data is read and shared with the patient during the consultation. Whether self-management data from devices and patient apps can be ingested and summarized is what turns CGM from "a device rental service" into a core instrument of care guidance.
Feature 4: Charting and orders — align documentation across professions
AI generates SOAP notes from consultation audio, set orders enter tests and prescriptions in one action, and templates can be registered and recalled.
The dialysis prevention fee requires a physician-nurse-dietitian team, the nutrition guidance fee a dietitian, and foot care dedicated physician and nurse staffing — each billing item involves different professions with its own documentation requirements. When record granularity varies by profession, proving compliance becomes difficult. Enforcing documentation templates at the system level directly protects both nurse and dietitian productivity and revenue capture.
Feature 5: Document generation — actually run the coordination add-on
AI drafts referral letters from patient data, output after physician review and correction.
The new ophthalmology and dental coordination add-ons (60 points each, once yearly) reward coordination anticipating retinopathy and periodontal disease. The add-on is annual, but the more eligible patients you have, the more referral letters you must write. Referral effort determines capture rate, so draft generation feeds straight into add-on realization.
Feature 6: Patient PHR app integration ("Pote-kun") — support an asymptomatic disease
Medication reminders, appointment booking, fee notifications, and LINE login with push notifications.
Diabetes produces few early symptoms. That makes acquisition hard — and it also makes visits and medication easy to abandon. Without symptoms, patients struggle to feel the necessity of treatment. Medication reminders and next-visit notifications act directly on that structural dropout risk. In a specialty where long-term continuing visits are the revenue base, continuation rate is the operating metric.
Feature 7: Audit and compliance — keep records of self-pay consent
All CRUD operations and access events are logged.
Self-pay GLP-1 provision sits in the area under the strongest advisories on off-label use and the tightest advertising scrutiny. Having a record of which patient received which explanation and gave which consent is a compliance defense. For the insured/self-pay split, being able to trace both billing history and explanation records is the desirable state.
Primary sources
- med-cpa, "FY2026 revision: lifestyle disease management fee changes" https://med-cpa.jp/hoshu-13/
- Funai Consulting, "Lifestyle disease management fee: impact of the 2026 revision" https://byoin-clinic-keiei.funaisoken.co.jp/blogs/column/life-0475
- Fujifilm/Medicom, "Raising per-visit revenue through guidance management fees" https://www.fujifilm.com/jp/ja/healthcare/clinic/column/advanced_management-guidance_management
- HOMER ION, "Diabetes dialysis prevention guidance management fee" https://www.homerion.co.jp/topics/gtes-dialysis-7/
- Certification Board for Diabetes Educators in Japan (CDEJ) https://www.cdej.or.jp/
- Abbott Japan, "FreeStyle Libre coverage expansion" https://www.abbott.co.jp/media-center/press-releases/03-04-2022.html
- Wemex/Medicom, "Key points for opening a diabetes clinic" https://www.phchd.com/jp/medicom/park/idea/opening-diabetology
- Med-Pro, "April 2026 clinic opening regulations" https://med-pro.jp/media.dr/2026/01/20/
- DCP Solution, "Key points of the 2026 opening regulations" https://dcp-sol.com/article/column/clinic-regulation-key-points-2026/
- Slimaru, "Wegovy insurance conditions and facility standards" https://slimaru.jp/article/wegovy-insurance